Elitek rasburicase regulatory update

FDA approved an sNDA from sanofi-aventis for Elitek rasburicase to manage plasma uric acid (PUA) levels in adults receiving anti-cancer therapy for leukemia, lymphoma or solid tumors likely to result ...